Next Article in Journal
Isolation and Identification of a TaTDR-Like Wheat Gene Encoding a bHLH Domain Protein, Which Negatively Regulates Chlorophyll Biosynthesis in Arabidopsis
Next Article in Special Issue
Interplay of Heme with Macrophages in Homeostasis and Inflammation
Previous Article in Journal
Immunological Memory of Psoriatic Lesions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 2
10.3390/ijms21020626
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease

by
Christina K. Ferrone
,
Mackenzie Blydt-Hansen
and
Michael J. Rauh
*
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(2), 626; https://doi.org/10.3390/ijms21020626
Submission received: 17 December 2019 / Revised: 10 January 2020 / Accepted: 13 January 2020 / Published: 17 January 2020
(This article belongs to the Special Issue Myeloid Cell Heterogeneity in Health and Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:
Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (TET2) are detected in peripheral blood cells of a remarkable 5%–10% of adults greater than 65 years of age. They impart a hematopoietic stem cell advantage and resultant clonal hematopoiesis of indeterminate potential (CHIP) with skewed myelomonocytic differentiation. CHIP is associated with an overall increased risk of transformation to a hematological malignancy, especially myeloproliferative and myelodysplastic neoplasms (MPN, MDS) and acute myeloid leukemia (AML), of approximately 0.5% to 1% per year. However, it is becoming increasingly possible to identify individuals at greatest risk, based on CHIP mutational characteristics. CHIP, and particularly TET2-mutant CHIP, is also a novel, significant risk factor for cardiovascular diseases, related in part to hyper-inflammatory, progeny macrophages carrying TET2 mutations. Therefore, somatic TET2 mutations contribute to myeloid expansion and innate immune dysregulation with age and contribute to prevalent diseases in the developed world—cancer and cardiovascular disease. Herein, we describe the impact of detecting TET2 mutations in the clinical setting. We also present the rationale and promise for targeting TET2-mutant and other CHIP clones, and their inflammatory environment, as potential means of lessening risk of myeloid cancer development and dampening CHIP-comorbid inflammatory diseases.

1. Introduction

Recent technological advancements have permitted the identification of a myriad of genes mutated in myeloid cancers [1,2,3,4,5,6,7]. TET2 is one of the most commonly mutated genes in these diseases, being highly involved in epigenetic regulation, including cytosine demethylation [5,8]. TET2-inactivating mutations also frequently occur in clonal hematopoiesis of indeterminate potential (CHIP), a “pre-leukemic” condition involving aberrant clonal expansion of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow [9,10]. Herein, we explore the importance of detecting mutations such as those observed in TET2 and its partner DNA-methyltransferase 3A (DNMT3A; another key epigenetic regulator, frequently mutated in CHIP and myeloid disease), and some of the associations of these genetic variations with CHIP and myeloid disease progression. We further discuss recent findings regarding CHIP, TET2 mutations and their connections to increased inflammation and comorbid disease. Finally, we briefly describe recent attempts to therapeutically increase wildtype TET2 protein levels or activity in the presence of heterozygous loss-of-function mutations.

2. Hematopoiesis and Myeloid Malignancies

Hematopoiesis is the production of mature blood cells from HSPCs. This process is polyclonal, with a range of approximately 50,000–200,000 HSPCs each giving rise to a fraction of mature blood cells [11]. Myeloid malignancies occur when individual HSPC mutant clones proliferate, expand and skew towards myeloid lineages. These include myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and acute myeloid leukemia (AML) (Figure 1) [1]. The WHO describes MDS as having “ineffective hematopoiesis”, characterized by abnormal hematopoietic cell shapes (morphological dysplasia) and peripheral cytopenia (low blood cell counts) [1]. MPN are characterized by the proliferation of mature myeloid cells, usually lacking morphological dysplasia, while myeloid neoplasms with clinical, laboratory, and morphologic features overlapping between MDS and MPN are classified as MDS/MPN [12]. AML involves the proliferation of immature myeloid cells (“blasts”) related to mutations that block normal HSPC differentiation and, like MPN, can involve recurrent mutations associated with cellular proliferation [1,12].

3. Unexplained Cytopenias and Shortcomings of Current Diagnostic Techniques

Unexplained blood cytopenia is another condition, in which individuals are deficient in one or more types of blood cell (red cells, white cells, or platelets), where the origin of this deficiency is not attributable to any identifiable cause or associated disease [16]. The current diagnostic approach for MDS relies primarily on morphological studies of peripheral blood and bone marrow aspirates to identify dysplasia, and on the presence of an abnormal karyotype [17]; however, many patients with unexplained cytopenias lack characteristic features of MDS and/or display normal karyotypes. Thus, it is difficult to reach a definitive diagnosis of MDS in patients with cytopenias due to the reliance on subjective morphological assessment. The classification of idiopathic cytopenia of undetermined significance (ICUS) was adopted to define a condition of unexplained blood cytopenia that doesn’t coincide with the diagnostic criteria of MDS [18]. Conversely, clonal cytopenia of undetermined significance (CCUS) is a new term used to classify patients with ICUS that are found to possess one or more somatic mutations [19]. This classification was introduced because recent studies have shown that many patients diagnosed with ICUS also possess MDS-associated somatic mutations, in addition to potentially sharing clinical and genetic characteristics with MDS patients (Figure 1) [19,20]. Given the subjective nature of morphological assessment, more accurate and precise diagnostic tools are necessary for early stage and existing myeloid neoplasms.

4. Promise of NGS in Myeloid Malignancy Diagnosis

Next-generation sequencing (NGS) has become increasingly important in the detection of genetic variants in myeloid malignancies [3,21,22]. Hematological variants identified through NGS impact diagnosis, in addition to revealing new prognostic, predictive, and therapeutic biomarkers in myeloid malignancies [21,22,23]. Several genes have been identified as recurrently mutated in these disorders, including epigenetic regulators (TET2, ASXL1, EZH2, DNMT3A, IDH1/IDH2), splicing factors (SF3B1, U2AF1, ZRSR2), genes involved in signal transduction (JAK2, KRAS, NRAS, CBL), among others [5,24,25]. For example, mutations in CALR or JAK2 are indicative of MPN [26], while FLT3, NPM1, and CEBPA are associated with AML [27]. Such mutations can also be prognostic indicators; e.g., the presence of TP53 or FLT3 mutations are associated with worse outcomes in AML [28,29]. Recent updates to the WHO classification of myeloid neoplasms have also begun to incorporate such mutations into diagnostic criteria. Notably, the previous MDS diagnosis of refractory anemia with ring sideroblasts (RARS) required a minimum of 15% ring sideroblasts to confirm a RARS diagnosis [12], while the updated diagnosis of MDS with ring sideroblasts (MDS-RS) requires only 5% ring sideroblasts when accompanied by an SF3B1 mutation (associated with mis-splicing of a mitochondrial iron transporter leading to abnormal accumulation of iron in mitochondria ringing the nucleus) [1].

5. CHIP and Risk of Hematological Malignancy

Hematopoietic cells tend to accumulate somatic mutations over time. It has been estimated that there are normally 50,000–200,000 HSPCs, and that they have a fidelity rate of approximately 0.78 × 10−9 mutations per genomic base pair per cell division, resulting in random mutations occurring at a rate of approximately 14 base substitutions and 0.13 coding mutations per year of life (i.e., approx. one mutation every 7–8 years) [7,11,30]. The prevalence of such mutations thus increases with age, but they generally do not impact normal HSPC function. However, some of these mutations can occur in genes that predispose them to malignant disease [7]. CHIP is a term used to describe individuals with hematological malignancy-associated somatic mutation(s) in the absence of other hematological malignancy diagnostic criteria [13,31]. Due to this accumulation of mutations over time, CHIP is especially common in the elderly population (>10% in those over 65 years of age), and therefore often referred to as age-related clonal hematopoiesis (ARCH) [9,13,32]. The minimum variant allele frequency (VAF) for genetic variants in individuals to meet the criteria for CHIP is ≥2% [13]. Furthermore, while CHIP is a clinical entity with specific criteria, including mutations in recognized cancer driver genes like TET2 and DNMT3A, the more general term clonal hematopoiesis (CH) describes a state in which a single hematopoietic stem cell clone gives rise to a disproportionate number of an individual’s mature blood cells. CH can include mutations at VAF <2% but may also arise without recognizable cancer driver mutations, possibly resulting from contraction and neutral drift in the HSPC pool [33].
Furthermore, the presence of such mutations is associated with an increased risk of progression to myeloid malignancies [9]. Increasing clonality of hematopoietic cells resulting from an accumulation of somatic mutations can lead to disease progression, where CHIP progresses to MDS for example, which can in turn transform to AML (associated with a poorer prognosis). CHIP is associated with an overall increased risk of progression to a hematological malignancy of approximately 0.5% to 1% per year [13]. Commonalities in mutational profiles suggest that blood cancers arise from earlier clones [32]. Importantly, the introduction of NGS technologies permitted the identification of these mutations in individuals without malignant disease, including mutations in TET2 (one of the most commonly mutated genes) [9,10].

6. TET2 and DNMT3A Mutations and Their Impact

TET2 is widely affected by mutations in myeloid neoplasms, and is one of the most commonly mutated genes in CHIP [9,32,34]. Somatic TET2 mutations are present in approximately 50% of chronic myelomonocytic leukemia (CMML; an MDS/MPN) cases, ~30% of MDS, and ~10% of AML [8]. Such TET2 loss-of-function mutations are associated with a DNA hypermethylation phenotype, tumour progression, and poor patient outcome [35,36]. DNA methylation plays a key role in proper HSPC self-renewal and lineage differentiation, and its dysregulation can lead to aberrant stem cell function and cellular transformation [37]. TET2 plays a crucial role in epigenetic modulation by promoting DNA demethylation [38]. DNA hypermethylation resulting from TET2 mutation is associated with CHIP, increased risk of MDS progression, and poor prognosis in AML [35]. The TET2 protein itself is one of the ten-eleven-translocation (TET1-3) proteins, which are alpha-ketoglutarate- and Fe2+-dependent dioxygenases (α-KGDDs). These α-KGDDs primarily catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) (Figure 2). These represent key intermediates in DNA demethylation through replication-dependent dilution or base excision repair [39].
Several studies have assessed the structure of the TET2 protein and the context of somatic mutations in myeloid malignancies, including the domains in which they occur. Whether mutations occur prior to or within the C-terminal catalytic domain of TET2, they generally result in loss of enzymatic function. Studies have shown that most commonly, nonsense or frameshift mutations occur before (and occasionally within) the catalytic domain, while missense mutations and in-frame deletions occur within the catalytic domain [8,40,41] (Figure 3). To our knowledge, a comprehensive comparison of TET2 mutations in CHIP versus myeloid malignancies has yet to be performed; however, the nature of TET2 CHIP mutations are also in keeping with TET2 catalytic inactivation. Overall, somatic mutations in TET2 have been found to occur in approximately 15% of patients with myeloid malignancies [8]. This gene therefore represents a promising molecular feature that can impact the clinical care of these patients. For example, the presence or absence of TET2 can be indicative of treatment outcome [42].
In 2014, Bejar et al. found that response to hypomethylating agents (HMA) in MDS patients is enhanced in those that exhibit clonal TET2 mutations [43]. They also found that the presence of additional mutations such as in ASXL1 indicate poorer prognosis [43], while another group found that overall survival is greater in patients with clonal TET2 mutations in the absence of ASXL1 mutations [44]. However, success of HMA treatment in MDS patients has been found to be inconsistent and dependent on particular combinations of mutations, though MDS patients are not currently denied HMA therapy based on the presence of certain mutations [45,46]. Additionally, the presence of TET2 mutations has been associated with reduced overall survival in patients with intermediate-risk AML [21]. Other studies have shown that co-mutations in DNMT3A and TET2 increase the risk of malignant transformation compared to either mutation alone [47,48], which is concerning given that these genes are frequently co-mutated in MDS [3].
The DNMT3A gene is affected by loss-of-function mutations in myeloid malignancies. It is an epigenetic regulator, where its associated protein, DNMT3A, catalyzes the methylation of CpG dinucleotides in genomic DNA [49]. Specifically, it catalyzes the covalent addition of a methyl group to the C5 position of cytosine (generating 5mC) [49,50]. DNMT3A is important in HSPC differentiation and helps regulate the function of stem cells. Loss-of-function in murine Dnmt3a leads to HSPC expansion, clonal dominance, aberrant DNA methylation, and eventually hematological malignancies [51]. The presence of a DNMT3A mutation in myeloid malignancies has also been shown to predict a higher likelihood of responding to an HMA [52]. Furthermore, DNMT3A mutations are associated with a worse prognosis in MDS when they occur in the presence of some other mutations, especially mutations in SF3B1 [53,54,55]. Mutations in DNMT3A also predict poor prognosis in AML [55].
Overall, the use of NGS to detect TET2, DNMT3A, and other mutations in patients with myeloid malignancies is imperative. These molecular features can be used as prognostic and diagnostic indicators for these patients, in addition to informing clinicians regarding the probability of disease progression and treatment options to improve patient care.

7. CHIP and Comorbid Diseases

While TET2 and DNMT3A mutations are two of most common genetic variations in CHIP and can precede myeloid malignancies, recent studies have also revealed associations between CHIP and other comorbid diseases [9,32]. Such studies have approached the identification of CHIP-associated diseases by genetically sequencing populations of elderly individuals who are more likely to harbour pathogenic somatic variants for CHIP, revealing that somatic changes in specific genes (especially TET2 and DNMT3A) are associated with increased risk of developing non-neoplastic diseases [9,32,33,56,57]. In a study in The New England Journal of Medicine in 2014, Jaiswal et al. observed an increase in all-cause mortality for individuals with CHIP, as well as a modestly elevated risk of type 2 diabetes. Individuals with CHIP also had strong associations with cardiovascular conditions. Notably, CHIP was associated with elevated risk of coronary heart disease and ischemic stroke [9].
In a more recent study, compared to individuals without CHIP, carriers of CHIP variants were found to be 1.9 times as likely to have coronary heart disease, 4.0 times as likely to experience early-onset myocardial infarction, and had increased coronary artery calcification [57]. In another study, somatic TET2 or DNMT3A variants in individuals with chronic ischemic heart disease appeared to associate with worse long-term clinical outcome due to heart failure. The VAF of clonal populations was associated with the severity of the clinical outcome, suggesting a dose-response relationship [58]. Similarly, aortic valve stenosis patients with DNMT3A or TET2 variants who underwent aortic valve implantation surgery were observed to have heightened medium-term all-cause mortality compared to those without CHIP mutations [59]. These results were supported by the finding that mice with hematopoietic or myeloid Tet2-deficiency had greater cardiac dysfunction and worsened remodeling following induced heart failure [60]. Hypercholesterolemic mice engrafted with either homozygous or heterozygous Tet2-knockout bone marrow developed larger atherosclerotic lesions than controls, suggesting that TET2 dysfunction contributes to the development of atherosclerotic plaques [57,61]. The increased lesion size in mice that received heterozygous Tet2-knockout bone marrow provides evidence for haploinsufficiency as a potential mechanism for atherogenesis. This is especially important considering that most individuals with TET2 somatic variants have only a single defective allele.
The involvement of hematological TET2-deficiency in the pathogenesis of atherosclerosis has been investigated at the cellular level [57,61]. Tet2-deficiency in myeloid cells was found to independently accelerate atherogenesis in mice and highlighted a potential role of Tet2-deficient macrophages as agents of atherosclerosis. Fuster et al. (2017) identified that Tet2-deficiency in murine macrophages facilitates nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-dependent production of the inflammatory cytokine interleukin 1 beta (IL-1b). IL-1b increases aortic expression of endothelial adhesion markers that recruit monocytes. Importantly, Tet2-deficient mice that were given an NLRP3 inhibitor had reduced size of atherosclerotic lesions and reduced expression of the endothelial adhesion marker [61]. A separate study arrived at similar conclusions, showing that Tet2-deficient mice treated with an NLRP3 inhibitor were protected against accelerated cardiac dysfunction [60]. These findings suggest that IL-1b or NLRP3 inflammasome inhibitors may be useful therapeutic approaches in the treatment or prevention of cardiovascular disease in people with TET2 mutations.
While somatic TET2 changes are common in myeloid malignancy, TET2 mutations have also been documented in the germline [62]. Interestingly, a family heterozygous for a truncating TET2 mutation had multiple cases of lymphoma among affected individuals but no abnormal cardiovascular phenotype [63]. Monocyte-derived macrophages that were isolated from TET2-mutation carriers showed a hypermethylation phenotype but did not have altered cytokine or chemokine secretion. This trend was affirmed in three unrelated individuals harbouring different germline TET2 mutations. Members of another family that were affected with a different heterozygous TET2 germline frameshift mutation all developed myeloid malignancy, possessed thyroid abnormalities, and had no history of cardiovascular disease [64]. The apparent phenotypic contrast between those with germline vs. somatic TET2 mutations merits further investigation with larger cohorts.
In addition to being associated with increased all-cause mortality, NGS has revealed that CHIP is significantly associated with chronic pulmonary disease [33,56]. Individuals with somatic variants in TET2 were found to have an elevated prevalence of self-reported asthma or chronic obstructive pulmonary disease (COPD), though the nature of this relationship is unclear [65]. Future studies will need to determine whether the relationship between TET2 mutations and COPD is mediated by smoking, or whether loss of function of TET2 plays a contributing role in the exacerbation of pulmonary diseases.
Regarding DNMT3A, variants in this gene in CHIP appear to be associated with the development of gastroesophageal reflux disease (GERD), whereas CHIP variants in TET2 or with VAF > 0.1 are potentially associated with elevated levels of circulating thyroid-stimulating hormone [56], although these require further validation. In addition, our unpublished data shows that Tet2-deficient mice spontaneously develop pulmonary arterial hypertension associated with increased lung inflammation. It is likely that subsequent studies will reveal further comorbidities associated with CHIP.

8. CHIP, Inflammation, and the Connection to the Pathogenesis of Myeloid Cancers

Many of the comorbid diseases associated with CHIP also have a shared inflammatory basis. Understanding the impact of inactivating TET2 and DNMT3A mutations on myeloid cells is critical for elucidating the connection between CHIP, inflammation, and the pathogenesis of comorbid disease, as well as myeloid malignancies. The TET2 protein plays a key role in myeloid cell function as an epigenetic regulator for cell differentiation and the inflammatory response. TET2 has been identified as a mediator of transcriptional regulation for inflammatory cytokines, notably interleukin 6 (IL6). During the resolution of inflammation, TET2 normally recruits histone deacetylase 2 (HDAC2) to deacetylate IL6, thereby repressing its transcription and IL-6 levels [66]. This epigenetic change is an important regulatory step for the termination of the inflammatory state in myeloid cells, especially macrophages and dendritic cells. In vitro, murine macrophages with Tet2 knocked out were observed to have upregulated Il6 expression, as well as upregulation of Il1b and arginase 1 (Arg1), during the late-phase response to lipopolysaccharides (LPS) exposure [67]. Tet2-knockout mice had elevated IL-6 production and were more prone to developing endotoxin shock and dextran-sulfate-sodium-induced colitis. Moreover, TET2 loss may alter the immune environment by interfering with other types of leukocytes, as Tet2-deficient murine T-cells showed aberrant cytokine signaling [68]. This suggests that the loss of Tet2 resulted in an exacerbated inflammatory phenotype, especially in myeloid cells.
It is well recognized that the prevalence of TET2 somatic variants increases with age [9,32,33]. However, the mechanism for the emergence and subsequent dominance of TET2-mutated clonal populations in elderly people has not been well studied. A recent study by Abegunde et al. (2018) showed that Tet2-knockout murine and TET2-deficient human HPSCs had a proliferative advantage when chronically exposed to tumour necrosis factor alpha (TNF-α) in vitro. Upon prolonged plating with TNF-α, HSPCs with inactivating TET2 mutations developed a resistance to apoptosis and a propensity for myeloid differentiation [69]. Similarly, upregulated Il6 expression from HSPCs in murine Tet2-knockout mice (in response to acute inflammatory stress) led to apoptotic resistance via increased expression of pro-survival genes and decreased expression of pro-apoptotic genes [70]. These results suggest that the expansion of TET2-mutated clones may be facilitated by a resistance to an inflammatory environment that these clones help propagate (Figure 4). Furthermore, another group found that microbial signals from the intestine appear to trigger the expansion of myeloid Tet2-deficient clones, where bacterial translocation in Tet2-knockout mice led to increased IL-6 production and myeloid expansion [71].
Regarding malignant disease, mutant HSPC clones have been found to alter the inflammatory microenvironment associated with the bone marrow, which can facilitate clonal expansion that leads to myeloid malignancies such as MDS [72]. This modified microenvironment becomes conducive to MDS development, often resulting from increased expression of proinflammatory genes such as IL1B, TNF and IL6, alterations in related immune cell subsets, and susceptibility to apoptosis within the bone marrow [72]. MDS can then progress to AML; in fact, approximately 40% of MDS cases progress [73].
Increased proinflammatory mediators can be produced by the mutant HSPC clone, macrophages, dendritic cells, and T-cells, among others. Mutations in TET2 (and other genes) can further promote proinflammatory gene expression. The resulting increase in inflammation can facilitate clonal expansion of mutant HSPCs and corresponding MDS pathogenesis or progression [72]. Macrophages, especially, have been shown to contribute to immune dysregulation and myeloid cancer pathogenesis in certain cases [74,75,76]. Other studies suggest that an abnormal immune environment in the bone marrow of patients with myeloid malignancies promotes genotoxic stress and pyroptosis, with the latter being mediated through activation of the NLRP3 inflammasome [77]. This in turn contributes to disease pathophysiology and clonal evolution that can lead to HSPC dysfunction [78,79,80].

9. Promises and Potential Pitfalls of Surveillance for CHIP in Human Aging

While CHIP is widely prevalent in elderly people and can pose serious health concerns through its associated risks, the question of how to effectively approach the clinical management and surveillance of CHIP is less clear. An important clinical objective for addressing CHIP should be the minimization of clonal expansions that contribute to disease states. Some have suggested that the selective destruction of mutant HSPCs is a valid strategy for the treatment of disorders originating from such HSPCs [10,13]. While this could prevent uncontrolled proliferation and subsequent disease, older individuals may rely on overly proliferative HSPCs to maintain normal blood cell levels. For such treatment to be considered, the benefit of reducing disease risk would have to be balanced with the potential health implications of treatment-induced cytopenias. Future management strategies should also address the effect of the CHIP inflammatory phenotype on broader comorbidities. Tet2-deficiency facilitates the upregulation of inflammatory cytokines (notably IL-1b) that contribute to the pathogenesis of atherosclerosis in mice [61]. Complementary to these findings, an IL-1b inhibitor has been shown to reduce the risk of recurrent cardiovascular events [81]. However, despite blocking IL-1b, residual IL-6 and interleukin 18 (IL-18) contribute to increased incidence of future cardiovascular events [82]. Another recent study showed that the presence of the IL-6 receptor (IL6R) p.Asp358Ala variant abolishes the cardiovascular risk in people with CHIP [83]. It appears that targeting the inflammatory outputs associated with dysregulated immune function may be a promising strategy for mitigating the risk of certain comorbidities in CHIP. To better understand this potential avenue of treatment, future research should seek to elucidate the mechanisms that underpin the pathogenesis of CHIP-associated diseases.
A diagnosis of CHIP can provide opportunities for management and preventative action. Hundreds of mutations in over fifty genes contribute to CHIP development [9]. These diverse mutational profiles may provide unique avenues to disease pathogenesis and an opportunity for personalized treatments. It is worth re-stating that the absolute risk for hematological cancer development in CHIP is low: 0.5% to 1.0% of individuals with CHIP develop myeloid cancer annually [9,32]. In addition, variants in TET2 and DNMT3A do not significantly lower the 10-year survival rate for elderly individuals (>85-year old) [84]. However, mutations in other CHIP-related genes have been found to associate with increased risk of and accelerated time to AML development [48,85]. Importantly, models have been constructed that can predict the development of AML either months or years in advance of disease onset by analyzing the somatic molecular profiles or clinical parameters (notably red blood cell distribution width) of people with CHIP [48]. Despite this recent progress, the risk associations between CHIP variants and other comorbid diseases remain poorly understood.
For CHIP surveillance to be implemented, it is important to consider the actionability of a CHIP diagnosis (i.e. its impact on clinical management). Identification of a pathogenic somatic variant in an otherwise hematological malignancy-free individual could warrant elevated follow-up frequencies to monitor potential progression. Individuals with other comorbidities that undergo testing for CHIP could benefit from a more informed prognosis based on the presence (or lack of) known pathogenic variants. Treatment plans for specific comorbidities, such as cardiovascular disease, could be individualized based on the calculated risk associated with testing results. However, studies concerning best practice for the treatment and prevention of CHIP-associated comorbidities have not yet been conducted, so the responsiveness of unique CHIP mutational profiles to various treatment approaches is not presently known. With CHIP clinics and related initiatives currently underway, we call for prospective studies at the involved institutions to help establish best practice recommendations.
The benefits of a CHIP diagnosis will also have to be balanced against the ramifications of screening healthy individuals. For example, using blood tests to screen for disease is invasive and risks provoking anxiety in patients. One should also consider potential ethical, legal, and financial issues (i.e. insurance eligibility) related to screening. An informed decision regarding the merit of CHIP surveillance in the general population will optimally account for all these factors.

10. Promise of Targeting the “Good Copy” of TET2

While several studies have assessed Tet2 loss-of-function in mice and reported associated HSPC aberrant self-renewal and myeloid lineage expansion [35], and though screening techniques have improved greatly in recent years to detect mutations in TET2 and other genes, therapeutic options to restore TET2 activity are currently lacking. In a recent study, Cimmino et al. (2017) modeled restoration of TET2 expression using reversible transgenic RNAi mice to confirm its reversal of aberrant HSPC self-renewal. Their study suggests that indirect restoration of TET2 function may offer a new therapeutic strategy for CHIP, MDS, and AML [39]. They found that Tet2 knockdown led to aberrant HSPC self-renewal, while Tet2 restoration reversed this effect in vitro and in vivo. Additionally, they found that Tet2-restored cells exhibited increased cell death, decreased proliferation, and priming toward myeloid differentiation [39]. These findings indicate that sustained TET2 deficiency is required for disease maintenance, and that restoration of TET2 may offer a viable therapeutic option for patients with myeloid malignancies possessing TET2 mutations.
Vitamin C is an α-KGDD co-factor that has been shown to promote activity of TET enzymes [86]. Administration of vitamin C has been tested, and demonstrated some efficacy, in the treatment of solid tumours [87]. To investigate the potential use of vitamin C in treating hematological malignancies, Cimmino and colleagues treated mouse HSPCs and human leukemia cells with vitamin C. They found that vitamin C treatment mimics TET2 restoration in Tet2-deficient mouse HSPCs by increasing 5hmC formation, as seen in other studies [88]. Similarly, Agathocleous et al. (2017) demonstrated that ascorbate (vitamin C) regulates TET2 function in hematopoietic stem cells (HSCs). They also found that feeding ascorbate to leukemogenic mice significantly extended survival, in addition to reducing myeloblasts in the blood, spleen cellularity and HPC frequency in the spleen [89]. While these findings support the use of vitamin C to treat TET2-deficient myeloid malignancies and potentially CHIP patients with TET2 mutations, the quantity of vitamin C required to achieve adequate TET2 level increases remains a barrier to effectively utilizing vitamin C as a treatment option for these patients. However, some more recent studies have begun to explore the use of ascorbate in a clinical setting in TET2-mutant patients [90,91], with one report demonstrating a clinical response of a patient with TET2-mutant AML to ascorbate, despite the TET2-mutant clone remerging at relapse [90].
Regarding targeting DNMT3A, few studies have explored the protein as a therapeutic target. While HMA treatment holds some promise for those mutations in DNMT3A, their toxicities remain too severe to justify use in patients with CHIP. However, some groups have begun to consider possible methods of targeting this protein. Rau et al. (2016) present a study in Blood that suggests that the histone lysine methyltransferase, disruptor of telomeric silencing 1-like (DOT1L) may represent a promising target in cases of DNMT3A-mutant AML. They demonstrated that pharmacologic inhibition of DOT1L in DNMT3A-mutant cell lines resulted in cell-cycle arrest and terminal differentiation, in addition to reducing cellular proliferation and inducing apoptosis in vitro [92]. Furthermore, Adema et al. (2017) published an abstract in Blood that demonstrated that S-adenosyl-l-methionine (SAM) supplementation in cases of monoallelic DNMT3A loss results in up-modulation of the wild-type DNMT3A allele in vitro [93]. These studies indicate promise in targeting levels of TET2 and DNMT3A in cases of heterozygous loss-of-function mutations, though further studies are needed before these therapeutic strategies could be considered from a clinical perspective.

11. Summary

Recent advances in genomic sequencing technologies have helped to characterize the phenotypic associations of acquired loss-of-function mutations in TET2, a gene that encodes an epigenetic regulator highly important for myeloid cell function. These mutations (along with variants in the DNMT3A gene) are associated with an increased risk of hematological malignancy and are especially prevalent in the elderly population. In addition, deficiency in TET2 provokes an inflamed immune phenotype (largely via aberrant cytokine secretion) and associates with several inflammation-based diseases, with a notable causal role in cardiovascular disease. Recently, mutational status and routine clinical information has been shown to predict future development of AML in individuals with CHIP. As a common and significant risk factor, the justification for screening at-risk individuals for TET2 mutation status must be balanced against potential ramifications of testing. While anti-inflammatory drugs can attenuate the cardiovascular risk, there are currently no viable therapeutic options for rescuing TET2 insufficiency in myeloid malignancies. Some approaches (notably vitamin C administration) have demonstrated restorative properties for TET2. However, barriers remain to these being effective treatments. Recent studies provide hope for future therapeutic strategies that may address loss-of-function mutations in both the TET2 and DNMT3A genes in cases of myeloid malignancies, and potentially even CHIP and comorbid diseases.

Author Contributions

Conceptualization, C.K.F. and M.J.R.; Writing—Original Draft Preparation and Writing—Review and Editing, C.K.F., M.B.-H., M.J.R.; Project Administration and Funding Acquisition, M.J.R. All authors have read and agreed to the published version of the manuscript.

Funding

Publication costs were supported by funding from the Southeastern Ontario Academic Medical Organization (S.E.A.M.O.) and the Innovation Fund, a joint initiative of the Ontario Ministry of Health and Long-Term Care (M.O.H.L.T.C.) and the Ontario Medical Association (O.M.A.) resulting from the Academic Health Science Centre Alternative Funding Plan.

Acknowledgments

Some figures were created using BioRender.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

α-KGDDsAlpha-ketoglutarate- and Fe2+-dependent dioxygenases
ARCHAge-related clonal hematopoiesis
Arg1Arginase 1
AMLAcute myeloid leukemia
CCUSClonal cytopenia of undetermined significance
CHClonal hematopoiesis
CHIPClonal hematopoiesis of indeterminant potential
CMMLChronic myelomonocytic leukemia
COPDChronic obstructive pulmonary disease
DNMT3ADNA methyltransferase 3 alpha
DOT1LDisruptor of telomeric silencing 1-like
GERDGastro-esophageal reflux disease
HDAC2Histone deacetylase 2
HMAHypomethylating agents
HSCHematopoietic stem cells
HSPCHematopoietic stem/progenitor cells
ICUSIdiopathic cytopenia of undetermined significance
IL-1βInterleukin 1 beta
IL-18Interleukin 18
IL-6Interleukin 6
IL6RInterleukin 6 receptor
LPSLipopolysaccharides
MDSMyelodysplastic syndromes
MDS-RSMDS with ring sideroblasts
MDS/MPNMyelodysplastic syndromes/myeloproliferative neoplasms
MPNMyeloproliferative neoplasm
NGSNext-generation sequencing
NLRP3Nod-like receptor family pyrin domain containing 3
RARSRefractory anemia with ring sideroblasts
SAMS-adenosyl-l-methionine
TET2Tet methylcytosine dioxygenase 2
TNF-αTumour necrosis factor alpha
VAFVariant allele frequency
5mC5-methylcytosine
5hmC5-hydroxymethylcytosine

References

  1. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2406. [Google Scholar] [CrossRef] [PubMed]
  2. Barbui, T.; Thiele, J.; Gisslinger, H.; Kvasnicka, H.M.; Vannucchi, A.M.; Guglielmelli, P.; Orazi, A.; Tefferi, A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J. 2018, 8, 15. [Google Scholar] [CrossRef] [PubMed]
  3. Haferlach, T.; Nagata, Y.; Grossmann, V.; Okuno, Y.; Bacher, U.; Nagae, G.; Schnittger, S.; Sanada, M.; Kon, A.; Alpermann, T.; et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28, 241–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Mardis, E.R.; Ding, L.; Dooling, D.J.; Larson, D.E.; McLellan, M.D.; Chen, K.; Koboldt, D.C.; Fulton, R.S.; Delehaunty, K.D.; McGrath, S.D.; et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361, 1058–1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Papaemmanuil, E.; Gerstung, M.; Malcovati, L.; Tauro, S.; Gundem, G.; Loo, P.V.; Yoon, C.J.; Ellis, P.; Wedge, D.C.; Pellagatti, A.; et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122, 3616–3627. [Google Scholar] [CrossRef]
  6. The Cancer Genome Atlas Research Network; Ley, T.J.; Miller, C.; Ding, L.; Raphael, B.J.; Mungall, A.J.; Robertson, G.; Hoadley, K.; Triche, T.J.; Laird, P.W.; et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368, 2059–2074. [Google Scholar] [CrossRef] [Green Version]
  7. Welch, J.S.; Ley, T.J.; Link, D.C.; Miller, C.A.; Larson, D.E.; Koboldt, D.C.; Wartman, L.D.; Lamprecht, T.L.; Liu, F.; Xia, J.; et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150, 264–278. [Google Scholar] [CrossRef] [Green Version]
  8. Delhommeau, F.; Dupont, S.; Della Valle, V.; James, C.; Trannoy, S.; Massé, A.; Kosmider, O.; Le Couedic, J.-P.; Robert, F.; Alberdi, A.; et al. Mutations in TET2 in cancer. N. Engl. J. Med. 2009, 360, 2289–2301. [Google Scholar] [CrossRef]
  9. Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.; Burtt, N.; Chavez, A.; et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 2014, 371, 2488–2498. [Google Scholar] [CrossRef] [Green Version]
  10. Shlush, L.I.; Zandi, S.; Mitchell, A.; Chen, W.C.; Brandwein, J.M.; Gupta, V.; Kennedy, J.A.; Schimmer, A.D.; Schuh, A.C.; Yee, K.W.; et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506, 328–333. [Google Scholar] [CrossRef]
  11. Lee-Six, H.; Øbro, N.F.; Shepherd, M.S.; Grossmann, S.; Dawson, K.; Belmonte, M.; Osborne, R.J.; Huntly, B.J.P.; Martincorena, I.; Anderson, E.; et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 2018, 561, 473–478. [Google Scholar] [CrossRef]
  12. Vardiman, J.W.; Thiele, J.; Arber, D.A.; Brunning, R.D.; Borowitz, M.J.; Porwit, A.; Lee Haris, N.; Le Beau, M.M.; Hellstrom-Lindberg, E.; Tefferi, A.; et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009, 114, 937–952. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Steensma, D.P.; Bejar, R.; Jaiswal, S.; Lindsley, R.C.; Sekeres, M.A.; Hasserjian, R.P.; Ebert, B.L. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015, 126, 9–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Bejar, R. CHIP, ICUS, CCUS and other four-letter words. Leukemia 2017, 31, 1869–1871. [Google Scholar] [CrossRef] [PubMed]
  15. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. (Eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.; International Agency for Research on Cancer: Lyon, France, 2017; Volume 2, Available online: http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017 (accessed on 3 June 2019).
  16. Malcovati, L.; Gall, A.; Travaglino, E.; Ambaglio, I.; Rizzo, E.; Molteni, E.; Elena, C.; Ferretti, V.V.; Catrical, S.; Bono, E.; et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 2017, 129, 3371–3379. [Google Scholar] [CrossRef] [PubMed]
  17. Steensma, D.P. Dysplasia has a differential diagnosis: Distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr. Hematol. Malig. Rep. 2012, 7, 310–320. [Google Scholar] [CrossRef]
  18. Valent, P.; Horny, H.-P.; Bennett, J.M.; Fonatsch, C.; Germing, U.; Greenberg, P.; Haferlach, T.; Haase, D.; Kolb, H.-J.; Krieger, O.; et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk. Res. 2007, 31, 727–736. [Google Scholar] [CrossRef]
  19. Kwok, B.; Hall, J.M.; Witte, J.S.; Xu, Y.; Reddy, P.; Lin, K.; Flamholz, R.; Dabbas, B.; Yung, A.; Al-Hafidh, J.; et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015, 126, 2355–2361. [Google Scholar] [CrossRef] [Green Version]
  20. Cargo, C.A.; Rowbotham, N.; Evans, P.A.; Barrans, S.L.; Bowen, D.T.; Crouch, S.; Jack, A.S. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015, 126, 2362–2365. [Google Scholar] [CrossRef] [Green Version]
  21. Patel, J.; Gönen, M.; Figueroa, M.E.; Fernandez, H.; Sun, Z.; Racevskis, J.; Van Vlierberghe, P.; Dolgalev, I.; Thomas, S.; Aminova, O.; et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 2012, 366, 1079–1089. [Google Scholar] [CrossRef] [Green Version]
  22. Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 2016, 374, 2209–2221. [Google Scholar] [CrossRef] [PubMed]
  23. Grossmann, V.; Kohlmann, A.; Eder, C.; Haferlach, C.; Kern, W.; Cross, N.C.; Haferlach, T.; Schnittger, S. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011, 25, 877–879. [Google Scholar] [CrossRef] [PubMed]
  24. Hofmann, I.; Elghetany, T.M. Myelodysplastic syndromes and myeloproliferative disorders. In Lanzkowsky’s Manual of Pediatric Hematology and Oncology; Academic Press: Cambridge, MA, USA, 2016; pp. 348–366. Available online: http://linkinghub.elsevier.com/retrieve/pii/B978012801368700017X (accessed on 16 March 2018).
  25. Chen, T.-C.; Hou, H.-A.; Chou, W.-C.; Tang, J.-L.; Kuo, Y.-Y.; Chen, C.-Y.; Tseng, M.-H.; Huang, C.-F.; Lai, Y.-J.; Chiang, Y.-C.; et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J. 2014, 4, e177. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, S.Y.; Im, K.; Park, S.N.; Kwon, J.; Kim, J.-A.; Lee, D.S. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: Primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am. J. Clin. Pathol. 2015, 143, 635–644. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Dombret, H. Gene mutation and AML pathogenesis. Blood 2011, 118, 5366–5367. [Google Scholar] [CrossRef] [PubMed]
  28. Fathi, A.T.; Chen, Y.-B. Treatment of FLT3-ITD acute myeloid leukemia. Am. J. Blood Res. 2011, 1, 175–189. [Google Scholar] [PubMed]
  29. Quintás-Cardama, A.; Hu, C.; Qutub, A.; Qiu, Y.H.; Zhang, X.; Post, S.M.; Zhang, N.; Coombes, K.; Kornblau, S.M. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 2017, 31, 1296–1305. [Google Scholar] [CrossRef]
  30. Osorio, F.G.; Rosendahl Huber, A.; Oka, R.; Verheul, M.; Patel, S.H.; Hasaart, K.; de la Fonteijne, L.; Varela, I.; Camargo, F.D.; van Boxtel, R. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 2018, 25, 2308–2316.e4. [Google Scholar] [CrossRef] [Green Version]
  31. Arends, C.M.; Galan-Sousa, J.; Hoyer, K.; Chan, W.; Jäger, M.; Yoshida, K.; Seemann, R.; Noerenberg, D.; Waldhueter, N.; Fleischer-Notter, H.; et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia 2018, 32, 1908–1919. [Google Scholar] [CrossRef]
  32. Genovese, G.; Kähler, A.K.; Handsaker, R.E.; Lindberg, J.; Rose, S.A.; Bakhoum, S.F.; Chambert, K.; Mick, E.; Neale, B.M.; Fromer, M.; et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014, 371, 2477–2487. [Google Scholar] [CrossRef] [Green Version]
  33. Zink, F.; Stacey, S.N.; Norddahl, G.L.; Frigge, M.L.; Magnusson, O.T.; Jonsdottir, I.; Thorgeirsson, T.E.; Sigurdsson, A.; Gudjonsson, S.A.; Gudmundsson, J.; et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017, 130, 1–3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Abdel-Wahab, O.; Mullally, A.; Hedvat, C.; Garcia-Manero, G.; Patel, J.; Wadleigh, M.; Malinge, S.; Yao, J.; Kilpivaara, O.; Bhat, R.; et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114, 144–147. [Google Scholar] [CrossRef] [PubMed]
  35. Guillamot, M.; Cimmino, L.; Aifantis, I. The impact of DNA methylation in hematopoietic malignancies. Trends Cancer 2016, 2, 70–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Jan, M.; Snyder, T.M.; Corces-Zimmerman, M.R.; Vyas, P.; Weissman, I.L.; Quake, S.R.; Majeti, R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 2012, 4, 149ra118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Jeong, M.; Goodell, M.A. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp. Hematol. 2014, 42, 609–617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Zhang, X.; Fu, R.; Yu, J.; Wu, X. DNA demethylation: Where genetics meets epigenetics. Curr. Pharm. Des. 2014, 20, 1625–1631. [Google Scholar] [CrossRef]
  39. Cimmino, L.; Dolgalev, I.; Wang, Y.; Yoshimi, A.; Martin, G.H.; Wang, J.; Ng, V.; Xia, B.; Witkowski, M.T.; Mitchell-Flack, M.; et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 2017, 170, 1079–1095.e20. [Google Scholar] [CrossRef] [Green Version]
  40. Hu, L.; Li, Z.; Cheng, J.; Rao, Q.; Gong, W.; Liu, M.; Shi, Y.G.; Zhu, J.; Wang, P.; Xu, Y. Crystal structure of TET2-DNA complex: Insight into TET-mediated 5mC oxidation. Cell 2013, 155, 1545–1555. [Google Scholar] [CrossRef] [Green Version]
  41. Langemeijer, S.M.C.; Kuiper, R.P.; Berends, M.; Knops, R.; Aslanyan, M.G.; Massop, M.; Stevens-Linders, E.; Van Hoogen, P.; Van Kessel, A.G.; Raymakers, R.A.P.; et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41, 838–842. [Google Scholar] [CrossRef]
  42. Mesa, R.A.; Jamieson, C.; Bhatia, R.; Deininger, M.W.; Fletcher, C.D.; Gerds, A.T.; Gojo, I.; Gotlib, J.; Gundabolu, K.; Hobbs, G.; et al. NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J. Natl. Compr. Cancer Netw. 2017, 15, 1193–1207. [Google Scholar] [CrossRef]
  43. Bejar, R.; Lord, A.; Stevenson, K.; Bar-Natan, M.; Perez-Ladaga, A.; Zaneveld, J.; Wang, H.; Caughey, B.; Stojanov, P.; Getz, G.; et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014, 124, 2705–2712. [Google Scholar] [CrossRef] [PubMed]
  44. Patnaik, M.M.; Lasho, T.L.; Vijayvargiya, P.; Finke, C.M.; Hanson, C.A.; Ketterling, R.P.; Gangat, N.; Tefferi, A. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016, 6, e385. [Google Scholar] [CrossRef] [Green Version]
  45. Nazha, A.; Sekeres, M.A.; Bejar, R.; Rauh, M.J.; Othus, M.; Komrokji, R.S.; Barnard, J.; Hilton, C.B.; Kerr, C.M.; Steensma, D.P.; et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. J. Clin. Oncol. Precis. Oncol. 2019, 3, 1–11. [Google Scholar] [CrossRef]
  46. Sekeres, M.A.; Othus, M.; List, A.F.; Odenike, O.; Stone, R.M.; Gore, S.D.; Litzow, M.R.; Buckstein, R.; Fang, M.; Roulston, D.; et al. Randomized Phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J. Clin. Oncol. 2017, 35, 2745–2753. [Google Scholar] [CrossRef] [PubMed]
  47. Zhang, X.; Su, J.; Jeong, M.; Ko, M.; Huang, Y.; Park, H.J.; Guzman, A.; Lei, Y.; Huang, Y.-H.; Rao, A.; et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat. Genet. 2016, 48, 1014–1023. [Google Scholar] [CrossRef] [Green Version]
  48. Abelson, S.; Collord, G.; Ng, S.W.K.; Weissbrod, O.; Mendelson Cohen, N.; Niemeyer, E.; Barda, N.; Zuzarte, P.C.; Heisler, L.; Sundaravadanam, Y.; et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 2018, 559, 400–404. [Google Scholar] [CrossRef]
  49. Heuser, M.; Thol, F.; Ganser, A. Clonal hematopoiesis of indeterminate potential. Dtsch. Arztebl. Int. 2016, 113, 317–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Chen, Z.X.; Riggs, A.D. DNA methylation and demethylation in mammal. J. Biol. Chem. 2011, 286, 18347–18353. [Google Scholar] [CrossRef] [Green Version]
  51. Yang, L.; Rau, R.; Goodell, M.A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 2015, 15, 152–165. [Google Scholar] [CrossRef]
  52. Traina, F.; Visconte, V.; Elson, P.; Tabarroki, A.; Jankowska, A.M.; Hasrouni, E.; Sugimoto, Y.; Szpurka, H.; Makishima, H.; O’Keefe, C.L.; et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014, 28, 78–87. [Google Scholar] [CrossRef]
  53. Martín, I.; Such, E.; Navarro, B.; Villamón, E.; Vicente, A.; Mora, E.; Pedrola, L.; Ibáñez, M.; López-Pavía, M.; Tormo, M.; et al. Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer J. 2017, 7, 630. [Google Scholar] [CrossRef] [Green Version]
  54. Martín, I.; Such, E.; Navarro, B.; Vicente, A.; López-Pavía, M.; Ibáñez, M.; Tormo, M.; Villamón, E.; Gómez-Seguí, I.; Luna, I.; et al. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). Leuk. Lymphoma 2017, 58, 1686–1693. [Google Scholar] [CrossRef]
  55. Lin, M.E.; Hou, H.A.; Tsai, C.H.; Wu, S.J.; Kuo, Y.Y.; Tseng, M.H.; Liu, M.C.; Liu, C.W.; Chou, W.C.; Chen, C.Y.; et al. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clin. Epigenet. 2018, 10, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Cook, E.K.; Izukawa, T.; Young, S.; Rosen, G.; Jamali, M.; Zhang, L.; Johnson, D.; Bain, E.; Hilland, J.; Ferrone, C.K.; et al. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019, 3, 2482–2486. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Jaiswal, S.; Natarajan, P.; Silver, A.J.; Gibson, C.J.; Bick, A.G.; Shvartz, E.; McConkey, M.; Gupta, N.; Gabriel, S.; Ardissino, D.; et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 2017, 377, 111–121. [Google Scholar] [CrossRef] [PubMed]
  58. Dorsheimer, L.; Assmus, B.; Rasper, T.; Ortmann, C.A.; Abou-El-Ardat, K.; Kiefer, K.C.; Hoffmann, J.; Seeger, F.; Bonig, H.; Dimmeler, S.; et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic Heart Failure. JAMA Cardiol. 2019, 4, 25–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Mas-Peiro, S.; Hoffmann, J.; Fichtlscherer, S.; Dorsheimer, L.; Rieger, M.A.; Dimmeler, S.; Vasa-Nicotera, M.; Zeiher, A.M. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur. Heart J. 2019, 1–7. [Google Scholar] [CrossRef] [Green Version]
  60. Sano, S.; Oshima, K.; Wang, Y.; MacLauchlan, S.; Katanasaka, Y.; Sano, M.; Zuriaga, M.A.; Yoshiyama, M.; Goukassian, D.; Cooper, M.A.; et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1B/NLRP3 inflammasome. J. Am. Coll. Cardiol. 2018, 71, 875–886. [Google Scholar] [CrossRef]
  61. Fuster, J.; MacLauchlan, S.; Zuriaga, M.; Polackal, M.N.; Ostriker, A.C.; Chakraborty, R.; Wu, C.L.; Sano, S.; Muralidharan, S.; Rius, C.; et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017, 355, 842–847. [Google Scholar] [CrossRef] [Green Version]
  62. Schaub, F.X.; Looser, R.; Li, S.; Hao-Shen, H.; Lehmann, T.; Tichelli, A.; Skoda, R.C. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115, 2003–2007. [Google Scholar] [CrossRef] [Green Version]
  63. Kaasinen, E.; Kuismin, O.; Rajamäki, K.; Ristolainen, H.; Aavikko, M.; Kondelin, J.; Saarinen, S.; Berta, D.G.; Katainen, R.; Hirvonen, E.A.M.; et al. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat. Commun. 2019, 10, 1252. [Google Scholar] [CrossRef] [PubMed]
  64. Duployez, N.; Goursaud, L.; Fenwarth, L.; Bories, C.; Marceau-Renaut, A.; Boyer, T.; Fournier, E.; Nibourel, O.; Roche-Lestienne, C.; Huet, G.; et al. Familial myeloid malignancies with germline TET2 mutation. Leukemia 2019. [Google Scholar] [CrossRef]
  65. Buscarlet, M.; Provost, S.; Zada, Y.F.; Barhdadi, A.; Bourgoin, V.; Lépine, G.; Mollica, L.; Szuber, N.; Dubé, M.P.; Busque, L. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 2017, 130, 753–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Zhang, Q.; Zhao, K.; Shen, Q.; Han, Y.; Gu, Y.; Li, X.; Zhao, D.; Liu, Y.; Wang, C.; Zhang, X.; et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015, 525, 389–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Cull, A.H.; Snetsinger, B.; Buckstein, R.; Wells, R.A.; Rauh, M.J. Tet2 restrains inflammatory gene expression in macrophages. Exp. Hematol. 2017, 55, 56–70. [Google Scholar] [CrossRef] [Green Version]
  68. Ichiyama, K.; Chen, T.; Wang, X.; Yan, X.; Kim, B.S.; Tanaka, S.; Ndiaye-Lobry, D.; Deng, Y.; Zou, Y.; Zheng, P.; et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 2015, 42, 613–626. [Google Scholar] [CrossRef] [Green Version]
  69. Abegunde, S.O.; Buckstein, R.; Wells, R.A.; Rauh, M.J. An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis. Exp. Hematol. 2018, 59, 60–65. [Google Scholar] [CrossRef]
  70. Cai, Z.; Kotzin, J.J.; Ramdas, B.; Chen, S.; Nelanuthala, S.; Palam, L.R.; Pandey, R.; Mali, R.S.; Liu, Y.; Kelley, M.R.; et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 2018, 23, 833–849. [Google Scholar] [CrossRef] [Green Version]
  71. Meisel, M.; Hinterleitner, R.; Pacis, A.; Chen, L.; Earley, Z.M.; Mayassi, T.; Pierre, J.F.; Ernest, J.D.; Galipeau, H.J.; Thuille, N.; et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 2018, 557, 580–584. [Google Scholar] [CrossRef]
  72. Cull, A.H.; Rauh, M.J. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes. J. Leukoc. Biol. 2017, 102, 209–219. [Google Scholar] [CrossRef]
  73. Heaney, M.L.; Golde, D.W. Myelodysplasia. N. Engl. J. Med. 1999, 340, 1649–1660. [Google Scholar] [CrossRef]
  74. Flores-Figueroa, E.; Gutiérrez-Espíndola, G.; Montesinos, J.J.; Arana-Trejo, R.M.; Mayani, H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk. Res. 2002, 26, 677–686. [Google Scholar] [CrossRef]
  75. Kitagawa, M.; Saito, I.; Kuwata, T.; Yoshida, S.; Yamaguchi, S.; Takahashi, M.; Tanizawa, T.; Kamiyama, R.; Hirokawa, K. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997, 11, 2049–2054. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Pang, W.W.; Pluvinage, J.V.; Price, E.A.; Sridhar, K.S.; Arber, D.A.; Greenberg, P.L.; Schrier, S.L.; Park, C.Y. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc. Natl. Acad. Sci. USA 2013, 110, 3011–3016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Basiorka, A.A.; Mcgraw, K.L.; Eksioglu, E.A.; Chen, X.; Johnson, J.; Zhang, L.; Zhang, Q.; Irvine, B.A.; Cluzeau, T.; Sallman, D.A.; et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 2016, 128, 2960–2975. [Google Scholar] [CrossRef]
  78. Yang, L.; Qian, Y.; Eksioglu, E.; Epling-Burnette, P.K.; Wei, S. The inflammatory microenvironment in MDS. Cell Mol. Life Sci. 2015, 72, 1959–1966. [Google Scholar] [CrossRef]
  79. Zambetti, N.A.; Ping, Z.; Chen, S.; Kenswil, K.J.G.; Mylona, M.A.; Sanders, M.A.; Hoogenboezem, R.M.; Bindels, E.M.J.; Adisty, M.N.; Van Strien, P.M.H.; et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 2016, 19, 613–627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Gañán-Gómez, I.; Wei, Y.; Starczynowski, D.T.; Colla, S.; Yang, H.; Cabrero-Calvo, M.; Bohannan, Z.S.; Verma, A.; Steidl, U.; Garcia-Manero, G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 2015, 29, 1458–1469. [Google Scholar] [CrossRef]
  81. Ridker, P.M.; Everett, B.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; Kastelein, J.J.P.; et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017, 377, 1119–1131. [Google Scholar] [CrossRef]
  82. Ridker, P.M.; Macfadyen, J.G.; Thuren, T.; Libby, P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1B inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J. 2019, 1–11. [Google Scholar] [CrossRef] [Green Version]
  83. Bick, A.G.; Pirruccello, J.P.; Griffin, G.K.; Gupta, N.; Gabriel, S.; Saleheen, D.; Libby, P.; Kathiresan, S.; Natarajan, P. Genetic IL-6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 2019. [Google Scholar] [CrossRef]
  84. Van den Akker, E.B.; Pitts, S.J.; Deelen, J.; Moed, M.H.; Potluri, S.; van Rooij, J.; Suchiman, H.E.; Lakenberg, N.; de Dijcker, W.J.; Uitterlinden, A.G.; et al. Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2. Blood 2016, 127, 1512–1515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Desai, P.; Mencia-trinchant, N.; Savenkov, O.; Simon, M.S.; Cheang, G.; Lee, S.; Samuel, M.; Ritchie, E.K.; Guzman, M.L.; Ballman, K.V.; et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 2018, 24, 1015–1023. [Google Scholar] [CrossRef] [PubMed]
  86. Blaschke, K.; Ebata, K.T.; Karimi, M.M.; Zepeda-Martínez, J.A.; Goyal, P.; Mahapatra, S.; Tam, A.; Laird, D.J.; Hirst, M.; Rao, A.; et al. Vitamin C induces TET-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013, 500, 222–226. [Google Scholar] [CrossRef]
  87. Fritz, H.; Flower, G.; Weeks, L.; Cooley, K.; Callachan, M.; McGowan, J.; Skidmore, B.; Kirchner, L.; Seely, D. Intravenous vitamin C and cancer. Integr. Cancer Ther. 2014, 13, 280–300. [Google Scholar] [CrossRef]
  88. Young, J.I.; Züchner, S.; Wang, G. Regulation of the epigenome by vitamin C. Annu. Rev. Nutr. 2015, 35, 545–564. [Google Scholar] [CrossRef] [Green Version]
  89. Agathocleous, M.; Meacham, C.E.; Burgess, R.J.; Piskounova, E.; Zhao, Z.; Crane, G.M.; Cowin, B.L.; Bruner, E.; Murphy, M.M.; Chen, W.; et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 2017, 549, 476–481. [Google Scholar] [CrossRef]
  90. Zhao, H.; Zhu, H.; Huang, J.; Zhu, Y.; Hong, M.; Zhu, H.; Zhang, J.; Li, S.; Yang, L.; Lian, Y.; et al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk. Res. 2018, 66, 1–7. [Google Scholar] [CrossRef]
  91. Das, A.B.; Kakadia, P.M.; Wojcik, D.; Pemberton, L.; Browett, P.J.; Bohlander, S.K.; Vissers, M.C.M. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. Blood Cancer J. 2019, 9, 82. [Google Scholar] [CrossRef]
  92. Rau, R.E.; Rodriguez, B.A.; Luo, M.; Jeong, M.; Rosen, A.; Rogers, J.H.; Campbell, C.T.; Daigle, S.R.; Deng, L.; Song, Y.; et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 2016, 128, 971–981. [Google Scholar] [CrossRef]
  93. Adema, V.; Balasubramanian, S.K.; Hirsch, C.M.; Przychodzen, B.P.; Phillips, J.G.; Lindner, D.; Radivoyevitch, T.; Mukherjee, S.; Nazha, A.; Carraway, H.E.; et al. Novel therapeutic targets for DNMT3A mutant myeloid neoplasms. Blood 2017, 130, 106. [Google Scholar] [CrossRef]
Ijms 21 00626 g001 550
Figure 1. Summary of current pre-neoplastic states and myeloid neoplasms. Pre-neoplastic states (in orange: clonal hematopoiesis of indeterminate potential, CHIP; idiopathic cytopenia of undetermined significance, ICUS; and clonal cytopenias of undetermined significance; CCUS) are classified primarily based on the presence of clonality (acquired DNA variants or chromosomal aberrations), and on the presence of peripheral cytopenias [13,14]. The main categories of myeloid neoplasm (blue) are primarily classified based on blast percentage (morphologically primitive cells, including HSPCs), by the type of cells that proliferate aberrantly, and by the morphology of the myeloid cells [15]. VAF, variant allele frequency; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; MDS/MPN, overlapping MDS and MPN; AML, acute myeloid leukemia.
Figure 1. Summary of current pre-neoplastic states and myeloid neoplasms. Pre-neoplastic states (in orange: clonal hematopoiesis of indeterminate potential, CHIP; idiopathic cytopenia of undetermined significance, ICUS; and clonal cytopenias of undetermined significance; CCUS) are classified primarily based on the presence of clonality (acquired DNA variants or chromosomal aberrations), and on the presence of peripheral cytopenias [13,14]. The main categories of myeloid neoplasm (blue) are primarily classified based on blast percentage (morphologically primitive cells, including HSPCs), by the type of cells that proliferate aberrantly, and by the morphology of the myeloid cells [15]. VAF, variant allele frequency; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; MDS/MPN, overlapping MDS and MPN; AML, acute myeloid leukemia.
Ijms 21 00626 g001
Ijms 21 00626 g002 550
Figure 2. Loss-of-function mutations in TET2 result in DNA hypermethylation. TET2 is an alpha-ketoglutarate- and Fe2+-dependent dioxygenase (α-KGDD) that catalyzes the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). This is a required step in proper DNA repair and DNA demethylation (green). Loss-of-function mutations in TET2 in CHIP and myeloid malignancies disrupt this oxidation step and result in a general DNA hypermethylation phenotype (red) and aberrant HSPC self-renewal, which is associated with an increased risk of CHIP, myeloid malignancy, MDS progression, and poor prognosis in AML [35].
Figure 2. Loss-of-function mutations in TET2 result in DNA hypermethylation. TET2 is an alpha-ketoglutarate- and Fe2+-dependent dioxygenase (α-KGDD) that catalyzes the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). This is a required step in proper DNA repair and DNA demethylation (green). Loss-of-function mutations in TET2 in CHIP and myeloid malignancies disrupt this oxidation step and result in a general DNA hypermethylation phenotype (red) and aberrant HSPC self-renewal, which is associated with an increased risk of CHIP, myeloid malignancy, MDS progression, and poor prognosis in AML [35].
Ijms 21 00626 g002
Ijms 21 00626 g003 550
Figure 3. Inactivating TET2 mutations occur throughout the coding region. The C-terminal catalytic domain of TET2 occurs approximately between amino acid residues 1129 and 1936, including a double-stranded β helix and cysteine-rich domain, binding sites for Fe(II) and α-ketoglutarate, as well as a low-complexity linker region. Together, these regions allow the catalytic domain of TET2 to bind to DNA, allowing the oxidation of 5mC to 5hmC [40]. Missense mutations and in-frame deletions occur in the catalytic domain of the protein (blue). Nonsense and frameshift mutations can occur throughout the entire coding region. However, they occur most frequently in the non-catalytic domain (green). Mutations in TET2 are generally inactivating regardless of their nature or location in the coding region of the gene [8,40,41].
Figure 3. Inactivating TET2 mutations occur throughout the coding region. The C-terminal catalytic domain of TET2 occurs approximately between amino acid residues 1129 and 1936, including a double-stranded β helix and cysteine-rich domain, binding sites for Fe(II) and α-ketoglutarate, as well as a low-complexity linker region. Together, these regions allow the catalytic domain of TET2 to bind to DNA, allowing the oxidation of 5mC to 5hmC [40]. Missense mutations and in-frame deletions occur in the catalytic domain of the protein (blue). Nonsense and frameshift mutations can occur throughout the entire coding region. However, they occur most frequently in the non-catalytic domain (green). Mutations in TET2 are generally inactivating regardless of their nature or location in the coding region of the gene [8,40,41].
Ijms 21 00626 g003
Ijms 21 00626 g004 550
Figure 4. Molecular pathogenesis of TET2-mutated HSPC. Exposure to upregulated inflammatory cytokines (due to systemic inflammation or local alterations) advantages TET2-mutant HSPCs, fostering a phenotype characterized by increased proliferation and a resistance to apoptosis [69,70,71]. TET2-mutant HSPCs and the abnormal immune microenvironment of the bone marrow can cause premature death or quiescence of wildtype (i.e., normal) HSPCs, consequently manifesting as ineffective and clonal hematopoiesis. The increased proliferation associated with TET2-mutant HSPCs leads to the expansion of TET2-clonal populations in the bone marrow and/or peripheral blood. Mature myeloid cells (e.g., macrophages) derived from TET2-mutant HSPCs demonstrate a hyper-inflammatory phenotype that contributes to the pathogenesis of comorbidities, with a notable causal role in cardiovascular disease [57,61,67].
Figure 4. Molecular pathogenesis of TET2-mutated HSPC. Exposure to upregulated inflammatory cytokines (due to systemic inflammation or local alterations) advantages TET2-mutant HSPCs, fostering a phenotype characterized by increased proliferation and a resistance to apoptosis [69,70,71]. TET2-mutant HSPCs and the abnormal immune microenvironment of the bone marrow can cause premature death or quiescence of wildtype (i.e., normal) HSPCs, consequently manifesting as ineffective and clonal hematopoiesis. The increased proliferation associated with TET2-mutant HSPCs leads to the expansion of TET2-clonal populations in the bone marrow and/or peripheral blood. Mature myeloid cells (e.g., macrophages) derived from TET2-mutant HSPCs demonstrate a hyper-inflammatory phenotype that contributes to the pathogenesis of comorbidities, with a notable causal role in cardiovascular disease [57,61,67].
Ijms 21 00626 g004

Share and Cite

MDPI and ACS Style

Ferrone, C.K.; Blydt-Hansen, M.; Rauh, M.J. Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. Int. J. Mol. Sci. 2020, 21, 626. https://doi.org/10.3390/ijms21020626

AMA Style

Ferrone CK, Blydt-Hansen M, Rauh MJ. Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. International Journal of Molecular Sciences. 2020; 21(2):626. https://doi.org/10.3390/ijms21020626

Chicago/Turabian Style

Ferrone, Christina K., Mackenzie Blydt-Hansen, and Michael J. Rauh. 2020. "Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease" International Journal of Molecular Sciences 21, no. 2: 626. https://doi.org/10.3390/ijms21020626

APA Style

Ferrone, C. K., Blydt-Hansen, M., & Rauh, M. J. (2020). Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. International Journal of Molecular Sciences, 21(2), 626. https://doi.org/10.3390/ijms21020626

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop